These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29243347)

  • 41. Motivational Interviewing to Encourage Quit Attempts Among Smokers Not Ready to Quit: A Trial-Based Economic Analysis.
    Rasu RS; Thelen J; Agbor Bawa W; Goggin K; Bradley-Ewing A; Catley D
    Nicotine Tob Res; 2020 Aug; 22(9):1515-1523. PubMed ID: 31820002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
    Vemer P; Rutten-van Mölken MP
    Value Health; 2010; 13(2):230-41. PubMed ID: 19804435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness Analysis of Smoking Cessation Interventions With Behavioral Support: A Study Based on the Benefits of Smoking Cessation on Outcomes (BENESCO) Model.
    Park SK; Kang DW; Lee EK
    Nicotine Tob Res; 2022 Nov; 24(12):2011-2017. PubMed ID: 35862219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Financial incentives to Medicaid smokers for engaging tobacco quit line treatment: maximising return on investment.
    Mundt MP; Baker TB; Piper ME; Smith SS; Fraser DL; Fiore MC
    Tob Control; 2020 May; 29(3):320-325. PubMed ID: 31147478
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re-treatment with varenicline is a cost-effective aid for smoking cessation.
    Kautiainen K; Ekroos H; Puhakka M; Liira H; Laine J; Linden K; Hahl J
    J Med Econ; 2017 Mar; 20(3):246-252. PubMed ID: 27754739
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness and cost-utility analysis of a work-place smoking cessation intervention with and without financial incentives.
    van den Brand FA; Nagelhout GE; Winkens B; Chavannes NH; van Schayck OCP; Evers SMAA
    Addiction; 2020 Mar; 115(3):534-545. PubMed ID: 31849138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The smoking cessation in pregnancy incentives trial (CPIT): study protocol for a phase III randomised controlled trial.
    Sinclair L; McFadden M; Tilbrook H; Mitchell A; Keding A; Watson J; Bauld L; Kee F; Torgerson D; Hewitt C; McKell J; Hoddinott P; Harris FM; Uny I; Boyd K; McMeekin N; Ussher M; Tappin DM;
    Trials; 2020 Feb; 21(1):183. PubMed ID: 32059684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards optimum smoking cessation interventions during pregnancy: a household model to explore cost-effectiveness.
    Saygın Avşar T; Jackson L; Barton P; Jones M; McLeod H
    Addiction; 2022 Oct; 117(10):2707-2719. PubMed ID: 35603912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
    Boyd KA; Briggs AH
    Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.
    Thomas KH; Dalili MN; López-López JA; Keeney E; Phillippo D; Munafò MR; Stevenson M; Caldwell DM; Welton NJ
    Health Technol Assess; 2021 Oct; 25(59):1-224. PubMed ID: 34668482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.
    Getsios D; Marton JP; Revankar N; Ward AJ; Willke RJ; Rublee D; Ishak KJ; Xenakis JG
    Pharmacoeconomics; 2013 Sep; 31(9):767-80. PubMed ID: 23821436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial.
    Li J; Hajek P; Pesola F; Wu Q; Phillips-Waller A; Przulj D; Myers Smith K; Bisal N; Sasieni P; Dawkins L; Ross L; Goniewicz ML; McRobbie H; Parrott S
    Addiction; 2020 Mar; 115(3):507-517. PubMed ID: 31597207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
    Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
    CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness Analysis of Varenicline Versus Currently Funded Smoking Cessation Strategies in Brazil.
    Fernandes RRA; Seixas BV; Szklo AS; Guerra RL; Barufaldi LA; de Albuquerque RCR; de Mello Vianna CM
    Value Health Reg Issues; 2022; 27():25-31. PubMed ID: 34784545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incentives for smoking cessation.
    Cahill K; Hartmann-Boyce J; Perera R
    Cochrane Database Syst Rev; 2015 May; (5):CD004307. PubMed ID: 25983287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
    Thavorn K; Chaiyakunapruk N
    Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-Effectiveness of a Health System-Based Smoking Cessation Program.
    Levy DE; Klinger EV; Linder JA; Fleegler EW; Rigotti NA; Park ER; Haas JS
    Nicotine Tob Res; 2017 Nov; 19(12):1508-1515. PubMed ID: 27639095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children.
    Johansson PM; Tillgren PE; Guldbrandsson KA; Lindholm LA
    Scand J Public Health; 2005; 33(5):343-52. PubMed ID: 16265801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
    Knight C; Howard P; Baker CL; Marton JP
    Value Health; 2010; 13(2):209-14. PubMed ID: 19912599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.